The study provides in vivo and in vitro evidence that USP19 functions as a negative regulator of pathological cardiac hypertrophy by inhibiting the TAK1‐p38/JNK1/2 signalling pathway in the hypertrophic hearts and cardiomyocytes. Here, MAPK8 is linked to cardiac hypertrophy.